AFP Immunohistochemistry Test at Lahore PCR Lab

AFP Immunohistochemistry at Lahore PCR Lab

Alpha-Fetoprotein (AFP) Immunohistochemistry (IHC) is a highly specialized pathology laboratory investigation performed on tissue biopsy specimens at Lahore PCR Lab in Lahore, Pakistan. AFP is an oncofetal glycoprotein primarily synthesized during fetal development by the embryonic yolk sac, fetal liver, and gastrointestinal tract. In healthy adults, serum levels of AFP are extremely low or undetectable, and normal adult tissues do not express this protein. However, certain neoplastic conditions, particularly hepatocellular carcinoma (HCC) and germ cell tumors such as yolk sac tumors, reactivate the expression of AFP. Immunohistochemical staining allows pathologists to visually detect the presence and localization of the AFP protein within tissue sections under a microscope, providing critical diagnostic, prognostic, and therapeutic insights.

The clinical importance of AFP Immunohistochemistry lies in its high specificity for identifying tumors of hepatic and germ cell origin. When a patient presents with an undefined mass in the liver, gonads, or retroperitoneum, histopathological evaluation alone can sometimes be inconclusive due to morphological overlap between different tumor types. AFP IHC acts as a definitive diagnostic tool by binding specific anti-AFP antibodies to the target antigens in the tissue. If AFP is present, a specialized enzyme-linked detection system produces a visible colored precipitate (usually brown), confirming the diagnosis. This advanced diagnostic capability at Lahore PCR Lab ensures that patients receive highly accurate diagnoses, which are essential for planning targeted oncological therapies, surgical resections, or systemic chemotherapeutic regimens.

Clinical Procedure: What to Expect

Patient Preparation

Because AFP Immunohistochemistry is a laboratory test performed on an already retrieved tissue specimen (such as a biopsy core, surgical resection, or fluid cytology block), there is no direct physical preparation required for the patient on the day of the IHC analysis itself. However, patients should be aware of the preparation required for the initial tissue collection procedure:

• Biopsy Preparation: If you are undergoing an image-guided needle biopsy (e.g., ultrasound or CT-guided liver biopsy) to obtain the tissue, you may need to fast for 4 to 6 hours prior to the procedure.
• Coagulation Profile: For invasive biopsies, physicians routinely require a complete blood count (CBC) and coagulation studies (PT/INR and APTT) to ensure safe blood clotting.
• Medication Adjustment: You must inform your clinical team of all medications you are currently taking, especially blood thinners like aspirin, warfarin, clopidogrel, or direct oral anticoagulants, which may need to be temporarily discontinued.
• Post-Procedure Care: Ensure you have arranged for a family member or friend to drive you home if your biopsy involves sedation or local anesthesia.

During the Procedure

The technical process of AFP Immunohistochemistry at Lahore PCR Lab is carried out by skilled histotechnologists and evaluated by consultant pathologists. The step-by-step laboratory workflow includes:

• Specimen Reception and Processing: The tissue specimen obtained via biopsy or surgery is fixed in 10% neutral buffered formalin to preserve cellular architecture. It is then processed and embedded in paraffin wax to create a formalin-fixed paraffin-embedded (FFPE) tissue block.
• Microtomy: Ultra-thin sections (approximately 3 to 5 micrometers thick) are cut from the paraffin block using a precision microtome and mounted onto specialized adhesive glass slides.
• Deparaffinization and Rehydration: The tissue slides are heated and treated with solvents like xylene and descending grades of alcohol to remove the paraffin wax and rehydrate the tissue.
• Antigen Retrieval: To expose the AFP epitopes that may have been masked during formalin fixation, the slides undergo heat-induced epitope retrieval (HIER) using specific buffer solutions in a controlled microwave or pressure cooker environment.
• Antibody Incubation: The slides are incubated with highly specific primary monoclonal or polyclonal antibodies directed against human Alpha-Fetoprotein.
• Detection and Visualization: After washing away unbound primary antibodies, a secondary biotinylated antibody or a polymer-based detection system is applied, followed by a chromogen substrate (typically diaminobenzidine or DAB). This chemical reaction produces a distinct brown cytoplasmic staining at the site of AFP antigen localization.
• Counterstaining and Mounting: The slides are counterstained with hematoxylin to provide cellular contrast (staining cell nuclei blue), dehydrated, cleared, and sealed with a coverslip for permanent storage and microscopic analysis.

When is an AFP Immunohistochemistry Performed?

Evaluation of Suspected Hepatocellular Carcinoma (HCC)

Physicians request AFP Immunohistochemistry when evaluating primary liver masses. Hepatocellular carcinoma is the most common primary malignancy of the liver, often arising in the setting of chronic hepatitis B or C infection, liver cirrhosis, or non-alcoholic fatty liver disease. When a liver biopsy shows atypical hepatocytic proliferation, AFP IHC is utilized to confirm a diagnosis of HCC, as the tumor cells frequently exhibit moderate-to-strong cytoplasmic positivity, helping to differentiate it from benign hepatic lesions or metastatic non-hepatic tumors.

Diagnosis of Germ Cell Tumors

AFP IHC is an indispensable marker in the diagnostic panel for gonadal and extragonadal germ cell tumors. It is highly sensitive for yolk sac tumors (also known as endodermal sinus tumors), which occur in the testes of young children and infants, as well as the ovaries of young women. Pathologists use AFP staining to identify yolk sac components within mixed germ cell tumors, which is vital because the presence of these components significantly influences the clinical staging, prognosis, and selection of chemotherapy protocols.

Differentiation of Liver Masses

Distinguishing between primary hepatocellular carcinoma and other hepatic malignancies, such as intrahepatic cholangiocarcinoma (bile duct cancer) or metastatic carcinomas from the gastrointestinal tract, breast, or lungs, can be challenging on routine hematoxylin and eosin (H&E) stained slides. AFP Immunohistochemistry is performed as part of a diagnostic antibody panel. While HCC cells are typically AFP-positive, cholangiocarcinomas and most metastatic adenocarcinomas are negative, allowing for a clear diagnostic distinction.

Investigation of Metastatic Tumors of Unknown Primary

When a patient presents with metastatic disease in lymph nodes, lungs, or bones without an obvious primary tumor site, pathologists utilize a panel of immunohistochemical stains to trace the tissue of origin. If the metastatic tumor cells show strong cytoplasmic expression of AFP, it strongly points toward a primary tumor originating in the liver (HCC) or a germ cell neoplasm, guiding the clinical team to focus their diagnostic imaging and therapeutic strategies on these specific organ systems.

Monitoring and Classification of Pediatric Hepatic Tumors

In pediatric pathology, distinguishing hepatoblastoma (the most common primary liver tumor in infants) from other childhood abdominal malignancies like neuroblastoma or Wilms’ tumor is critical. Hepatoblastoma subtypes, particularly the epithelial and fetal variants, often show varying degrees of AFP immunoreactivity. Performing AFP IHC helps pathologists classify the specific tumor subtype, which correlates directly with the tumor’s biological behavior and response to pediatric oncological treatments.

What Does an AFP Immunohistochemistry Detect?

AFP Immunohistochemistry detects the intracellular presence, distribution, and intensity of Alpha-Fetoprotein within tissue samples. Specifically, the test identifies:

• Cytoplasmic Expression: The characteristic brown staining localized within the cytoplasm of neoplastic cells.
• Hepatocellular Carcinoma Cells: Confirms the hepatic lineage of malignant cells in liver biopsies.
• Yolk Sac Tumor Components: Identifies classic reticular, microcystic, or solid patterns of yolk sac tumors.
• Schiller-Duval Bodies: Highlights these pathognomonic structures in yolk sac tumors, which express AFP strongly.
• Embryonal Carcinoma Focal Positivity: Detects scattered AFP-positive cells in embryonal carcinomas, indicating early yolk sac differentiation.
• Hepatoid Adenocarcinoma: Identifies rare, aggressive variants of gastric, lung, or ovarian cancers that morphologically and immunophenotypically mimic HCC.
• Sertoli-Leydig Cell Tumors: Detects heterologous hepatoid elements within these specialized ovarian sex cord-stromal tumors.
• Fetal Liver Elements: Identifies normal developmental expression in fetal or neonatal tissue controls.
• Regenerative Hepatocytes: Detects weak, focal, or transient AFP expression in regenerating liver tissue following acute injury or partial hepatectomy.
• Cirrhotic Nodule Activity: Evaluates low-level AFP expression in highly active cirrhotic nodules, aiding in the surveillance of pre-malignant changes.
• Clear Cell Components: Helps differentiate clear cell variants of HCC from clear cell renal cell carcinoma.
• Solid Tumor Heterogeneity: Maps the distribution of AFP-producing cells within a heterogeneous tumor mass.
• Treatment-Induced Changes: Assesses residual viable tumor cells expressing AFP after transarterial chemoembolization (TACE) or systemic therapy.
• Metastatic Germ Cell Disease: Confirms the germ cell origin of metastatic lesions in retroperitoneal lymph nodes.
• Epithelial Hepatoblastoma: Detects strong positivity in fetal-type epithelial cells of pediatric hepatoblastomas.
• Anaplastic Tumor Lineage: Aids in defining the lineage of highly undifferentiated abdominal or pelvic masses.
• Mixed Germ Cell Tumor Composition: Quantifies the proportion of yolk sac tumor elements relative to seminoma, dysgerminoma, or choriocarcinoma.
• Hepatoid Yolk Sac Tumor Variant: Distinguishes this specific variant from classic yolk sac tumor configurations.
• Bile Duct Infiltration: Confirms the absence of AFP in neoplastic bile duct epithelium, ruling out classic cholangiocarcinoma.
• Diagnostic Panel Integration: Works in conjunction with Glypican-3, HepPar-1, Arg-1, and CD10 to establish a definitive hepatobiliary profile.

Turnaround Time and Report Access at Lahore PCR Lab

At Lahore PCR Lab, histopathology and immunohistochemistry investigations are processed with the highest standards of clinical accuracy and quality control. Because immunohistochemistry involves multiple sequential laboratory steps—including tissue fixation, paraffin embedding, microtomy, antigen retrieval, antibody incubation, and expert microscopic evaluation—the turnaround time for an AFP IHC report typically ranges from 3 to 5 working days. This timeline ensures that the tissue undergoes optimal processing and that the staining is meticulously reviewed by a consultant pathologist.

Once the diagnostic report is finalized and signed off by the pathologist, Lahore PCR Lab provides convenient methods for patients and referring physicians to access the results. Reports can be collected physically from the main laboratory reception in Lahore. Additionally, patients can access and download their reports digitally through the Lahore PCR Lab online portal or via automated WhatsApp delivery services, facilitating prompt clinical decision-making and timely initiation of treatment.

AFP Immunohistochemistry Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Adult Hepatocytes	Negative (No cytoplasmic staining)	Diffuse or focal cytoplasmic positivity (indicative of Hepatocellular Carcinoma or active regeneration)
Bile Duct Epithelium	Negative	Negative in classic cholangiocarcinoma; positive only in extremely rare hepatoid variants
Yolk Sac Elements	Negative (Absent in normal adult gonads)	Strong, diffuse cytoplasmic staining (diagnostic of Yolk Sac Tumor)
Embryonal Carcinoma	Negative	Focal, patchy cytoplasmic positivity (suggesting early yolk sac differentiation)
Seminoma / Dysgerminoma	Negative	Negative (helps differentiate from yolk sac tumor and embryonal carcinoma)
Metastatic Adenocarcinoma	Negative	Negative in most cases; positive in hepatoid adenocarcinoma of gastric or pulmonary origin
Regenerating Liver Nodules	Negative to weak, rare focal staining	Focal, weak-to-moderate staining in areas of active, intense hepatocyte regeneration
Hepatoblastoma Tissue	Negative (Absent in normal pediatric liver)	Variable moderate-to-strong cytoplasmic positivity in epithelial components

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Lahore PCR Lab for AFP Immunohistochemistry?

• Experienced Healthcare Professionals: Our pathology department is led by highly qualified consultant pathologists specializing in histopathology and immunohistochemistry.
• Patient-Focused Care: We prioritize patient comfort, clear communication, and compassionate support throughout the diagnostic journey.
• Quality Diagnostic Services: Lahore PCR Lab adheres to strict internal and external quality control protocols to ensure the highest accuracy in tissue staining.
• Professional Reporting: Detailed diagnostic reports include comprehensive immunophenotypic profiles to assist oncologists in treatment planning.
• Modern Diagnostic Approach: We utilize advanced antigen retrieval systems and high-affinity primary antibodies for superior staining sensitivity.
• Comfortable Environment: Our diagnostic center in Lahore offers a clean, professional, and welcoming environment for all patients.
• Convenient Location: Easily accessible main laboratory and collection centers located across Lahore, Pakistan.
• Commitment to Accurate Diagnosis: We understand the critical nature of oncology diagnostics and are dedicated to delivering reliable, timely results.